^(89)Sr治疗老年患者前列腺癌骨转移骨痛的临床观察

Clinical observation on strontium-89-chloride therapy in elder patients with prostate cancer for palliation of pain from bone metastases

目的评价89SrCl2对老年患者前列腺癌骨转移伴骨痛的临床疗效及不良反应。方法对外科去势治疗术后的老年患者前列腺癌骨转移伴有不同程度骨痛患者48例,使用89SrCl2静脉注射治疗,观察其镇痛效果、骨转移灶的变化、前列腺特异性抗原(PSA)及不良反应等。结果48例患者接受89Sr治疗后,止痛的总有效率达89·6%,无效10·4%,骨转移灶有明显减少。对PSA有不同程度的下降。所有治疗者均未发现严重的不良反应和毒副作用。结论89SrCl2对去势治疗术后的老年患者前列腺癌骨转移骨痛的临床止痛疗效明显,特别是对多发骨转移癌伴骨痛患者是一种有效的治疗方法。

Objective To estimate clinical curative efficacy and adverse reaction of 89^Sr-chloride therapy for palliation of pain from bone metastases in the older patients with prostate cancer. Methods 48 cases of older patients with metastatic prostate cancer with bone pain were studied after androgen deprivation therapy, 89^ Sr-chloride were administrated iv for the palliative treatment of metastatic bone pain. The curative effects in patients were investigated, including palliation of pain, change of metastatic focus, the tumor sign of PSA, and the adverse reaction. Results After 89 ^Sr-chloride therapy, the total palliation rate was 89.6% , inefficiency rate was 10.4%, while metastatic focus and PSA decreased to some extent. No severe adverse reaction occurred. Conclusions It is shown that the curative efficacy of acesodyne is evident after 89^ Sr-chloride therapy in older patients suffering from bone metastase with prostate cancer. It is an effective therapeutic method for the palliation of pain from bone metastases especiallly to the older patients with multiple metastatases.